GeoVax moves higher before the bell as traders watch for Mpox vaccine news
GeoVax Labs shares more than doubled in U.S. pre-market trading Monday, quoted at $2.34–$2.61 after closing Friday at $1.23. The surge followed last week’s first-quarter update and news of a planned Phase 3 trial for its GEO-MVA vaccine, not a new clinical result. GeoVax reported $1.27 million in cash at March 31 and warned it may need new funding by June 2026.